Gabapentin
Gabapentinoids
Sold as GABARONE · NEURONTIN
- Drug class
- Gabapentinoids
- Availability
- Prescription only
- Routes
- Oral
- Markets covered
- 3
- Products on record
- 252
- FDA reports (12 mo)
- 16,900
Overview
Plain-language summary, compiled from the cited regulatory records
Gabapentin is an active pharmaceutical ingredient classified as a gabapentinoid [1]. It is approved for specific medical uses in adults and pediatric patients.
Gabapentin is indicated for the management of postherpetic neuralgia in adults [1]. It is also approved as an adjunctive therapy for treating partial onset seizures, with or without secondary generalization, in adults and pediatric patients aged 3 years and older who have epilepsy [1]. This medication is available under various brand names, including GABARONE [1].
In the past 12 months, there have been 16,900 adverse event reports associated with gabapentin [2]. Common reasons for these reports include off-label use, nausea, fatigue, perceived drug ineffectiveness, and diarrhea [2].
This is not medical advice. Consult a qualified healthcare professional.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 133 | May 29, 2026 |
| CA Canada | Health Canada | 77 | May 28, 2026 |
| US United States | FDA | 42 | May 28, 2026 |
GBUnited Kingdom· MHRA
133 products
Uses
1). Gabapentin is indicated as monotherapy in the treatment of partial seizures with and without secondary generalization in adults and adolescents aged 12 years and above. Treatment of peripheral neuropathic pain Gabapentin is indicated for the treatment of peripheral neuropathic pain such as painful diabetic neuropathy and post-herpetic neuralgia in adults.
How to take
CACanada· Health Canada
77 products
Uses
Adults GABAPENTIN CAPSULES (Gabapentin Capsules) is indicated as adjunctive therapy for the management of patients with epilepsy who are not satisfactorily controlled with conventional therapy. 1 Pediatrics Pediatrics (< 18 years of age): Based on the data submitted and reviewed by Health Canada, the safety and efficacy of gabapentin in pediatric patients has not been established; therefore, Health Canada has not authorized an indication for pediatric use.
3 Pediatrics). 2 Geriatrics Geriatrics (> 65 years of age): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for geriatric use. 4 Geriatrics).
How to take
USUnited States· FDA
42 products
Uses
1 INDICATIONS AND USAGE Gabapentin is indicated for: • Management of postherpetic neuralgia in adults • Adjunctive therapy in the treatment of partial onset seizures, with and without secondary generalization, in adults and pediatric patients 3 years and older with epilepsy Gabapentin is indicated for: • Postherpetic neuralgia in adults ( 1 ) • Adjunctive therapy in the treatment of partial onset seizures, with and without secondary generalization, in adults and pediatric patients 3 years and older with epilepsy ( 1 )
How to take
Drug interactions
Known interactions involving Gabapentin. Select one for details. This list is informational and not a complete interaction checker.
Showing 240 of 553. Type above to find a specific drug.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]MHRA (UK) · PL163630285 · revised May 29, 2026
- [2]Health Canada (DPD) · 02530961 · revised May 28, 2026
- [3]FDA DailyMed · 03031adf-d36b-45… · revised May 28, 2026 [PDF]
- [4]OpenFDA adverse-event reports (US), 12 months ending June 4, 2026.
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.